Panobacumab

Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.[1]

Panobacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPseudomonas aeruginosa serotype IATS O11
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC38714H60189N10637O12187S322
Molar mass879959.96 g·mol−1
 NY (what is this?)  (verify)

It is a fully human pentameric IgM antibody with a mouse J chain.[1]

Panobacumab molecule consisting of five base units.
1: Base unit.
2: Heavy chains.
3: Light chains.
4: J chain.
5: Intermolecular disulfide bonds.

Development

Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.[2]

The mechanism of action is as a lipopolysaccharide inhibitor.[2]


References
  1. International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. https://adisinsight.springer.com/drugs/800024401. Retrieved 15 November 2019. Missing or empty |title= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.